Hsbc Holdings PLC Grows Position in STERIS plc $STE

Hsbc Holdings PLC grew its position in STERIS plc (NYSE:STE) by 352.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,320 shares of the medical equipment provider’s stock after purchasing an additional 137,355 shares during the period. Hsbc Holdings PLC’s holdings in STERIS were worth $38,958,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of STE. Vanguard Group Inc. increased its position in STERIS by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock worth $3,114,882,000 after purchasing an additional 73,014 shares in the last quarter. State Street Corp lifted its position in STERIS by 6.0% during the fourth quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock valued at $1,169,957,000 after buying an additional 260,001 shares in the last quarter. Geode Capital Management LLC grew its stake in STERIS by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock worth $637,259,000 after buying an additional 14,151 shares during the period. Orbis Allan Gray Ltd grew its stake in STERIS by 5.6% during the fourth quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock worth $570,296,000 after buying an additional 120,200 shares during the period. Finally, AQR Capital Management LLC grew its stake in STERIS by 37.2% during the fourth quarter. AQR Capital Management LLC now owns 1,623,234 shares of the medical equipment provider’s stock worth $411,522,000 after buying an additional 440,164 shares during the period. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Transactions at STERIS

In other STERIS news, CEO Daniel A. Carestio sold 1,374 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $212.00, for a total value of $291,288.00. Following the transaction, the chief executive officer directly owned 63,647 shares of the company’s stock, valued at $13,493,164. This represents a 2.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP John Adam Zangerle sold 1,419 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $209.28, for a total value of $296,968.32. Following the transaction, the vice president owned 35,259 shares of the company’s stock, valued at approximately $7,379,003.52. This trade represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 7,328 shares of company stock valued at $1,554,051. 1.12% of the stock is currently owned by insiders.

STERIS Stock Down 1.5%

Shares of NYSE:STE opened at $214.58 on Tuesday. The company has a market capitalization of $20.91 billion, a price-to-earnings ratio of 27.06 and a beta of 0.92. The company has a 50 day moving average of $211.74 and a two-hundred day moving average of $228.57. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25.

STERIS (NYSE:STE) last announced its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. STERIS’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter last year, the company posted $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, analysts forecast that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 26th. Stockholders of record on Monday, June 8th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, June 8th. STERIS’s payout ratio is presently 31.78%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings cut shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Piper Sandler reaffirmed an “overweight” rating and set a $270.00 price target on shares of STERIS in a research report on Thursday, May 21st. Finally, KeyCorp lowered their price target on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.